Literature DB >> 5158780

Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism.

R J Mones, T S Elizan, G J Siegel.   

Abstract

An analysis of 51 patients with Parkinsonism who have developed L-dopa induced dyskinesias is presented. The cause has not been proven, although various hypotheses are discussed. One third of the total number of patients treated developed dyskinesia. These patients tend to respond better to L-dopa than the other group. There is a tendency for the older patient or the patient with long-standing disease to develop dyskinesias. There appears to be no way of predicting which patients will develop dyskinesia by analysis of the symptoms or the aetiology of the Parkinsonism syndrome. The unilateral characteristic of the dyskinesia in patients with hemi-Parkinsonism and patients with unilateral thalamotomies suggests that structural abnormalities are critical in determining the presence and localization of dyskinesias. This is supported by non-occurrence of similarly treated patients without Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5158780      PMCID: PMC1083499          DOI: 10.1136/jnnp.34.6.668

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase.

Authors:  G Bartholini; M Da Prada; A Pletscher
Journal:  J Pharm Pharmacol       Date:  1968-03       Impact factor: 3.765

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Similarities between neurologic effects of L-dopa and of apomorphine.

Authors:  G C Cotzias; P S Papavasiliou; C Fehling; B Kaufman; I Mena
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

4.  Serotonin and dopamine in the extrapyramidal system.

Authors:  T L Sourkes; L J Poirier
Journal:  Adv Pharmacol       Date:  1968

5.  Striatal amines, experimental tremor and the effect of harmaline in the monkey.

Authors:  L J Poirier; T L Sourkes; G Bouvier; R Boucher; S Carabin
Journal:  Brain       Date:  1966-03       Impact factor: 13.501

6.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS.

Authors:  A M Ernst
Journal:  Psychopharmacologia       Date:  1965-05-21

9.  Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats.

Authors:  A M Ernst; P G Smelik
Journal:  Experientia       Date:  1966-12-15

10.  Relation between the structure of certain methoxyphenylethylaminederivatives and the occurrence of a hypokinetic rigid syndrome.

Authors:  A M Ernst
Journal:  Psychopharmacologia       Date:  1965-05-21
View more
  22 in total

Review 1.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Treatment of Parkinson's syndrome with L-DOPA on an out-patient basis.

Authors:  C Fehling
Journal:  Z Neurol       Date:  1972

3.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Management of parkinson's disease--combined therapy with levodopa and thalamotomy.

Authors:  J A Mosso; R W Rand
Journal:  West J Med       Date:  1975-01

Review 5.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

6.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

8.  An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.

Authors:  R J Mones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-06       Impact factor: 10.154

9.  Unilateral vs. bilateral STN DBS effects on working memory and motor function in Parkinson disease.

Authors:  T Hershey; J Wu; P M Weaver; D C Perantie; M Karimi; S D Tabbal; J S Perlmutter
Journal:  Exp Neurol       Date:  2007-11-29       Impact factor: 5.330

10.  Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.

Authors:  Kathy Steece-Collier; Katherine E Soderstrom; Timothy J Collier; Caryl E Sortwell; Eleonora Maries-Lad
Journal:  J Comp Neurol       Date:  2009-07-01       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.